Negative Trials

15

description

Negative Trials. TRILOGY ACS No significant difference in ischemic outcomes despite greater P2Y 12 receptor inhibition with prasugrel than with clopidogrel. ISIS-2, GUSTO: Exclusion Criteria. Today’s Trial Design Challenges. NIH Health Care Systems Research Collaboratory. - PowerPoint PPT Presentation

Transcript of Negative Trials